Patents by Inventor Igor C. Almeida

Igor C. Almeida has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230009415
    Abstract: Disclosed are neoglycoconjugates and/or glycosides containing glycan selected from Galp?1,3Galf?, Galp?1,6Galp?1,3Galf?, or Galp?1,3Galf?1,3Manp?. Methods of using the glycosides and/or neoglycoconjugates as diagnostic or prognostic biomarkers, vaccines, treating or detecting parasitic diseases, such as cutaneous leishmaniasis are disclosed.
    Type: Application
    Filed: July 1, 2022
    Publication date: January 12, 2023
    Inventors: Katja Michael, Igor C. Almeida, Rosa A. Maldonado, Alvaro Acosta-Serrano, Alba A. Montoya, Susana Portillo
  • Patent number: 10918732
    Abstract: Certain embodiments are directed to method for synthesizing and using glycoconjugates based on the immunodominant epitope Gal?(1,3)Gal?(1,4)GlcNAc? (Gal?3LN?).
    Type: Grant
    Filed: July 26, 2019
    Date of Patent: February 16, 2021
    Assignee: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Igor C. Almeida, Katja Michael, Nathaniel Schocker, Susana Portillo, Rosa Maldonado
  • Publication number: 20190343960
    Abstract: Certain embodiments are directed to method for synthesizing and using glycoconjugates based on the immunodominant epitope Gal?(1,3)Gal?(1,4)GlcNAc? (Gal?3LN?).
    Type: Application
    Filed: July 26, 2019
    Publication date: November 14, 2019
    Applicant: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Igor C. ALMEIDA, Katja MICHAEL, Nathaniel SCHOCKER
  • Patent number: 10363319
    Abstract: Certain embodiments are directed to method for synthesizing and using glycoconjugates on the immunodominant epitope Gal?(1,3)Gal?(3(1,4)GlcNAc? (Gal?3LN?).
    Type: Grant
    Filed: October 31, 2015
    Date of Patent: July 30, 2019
    Assignee: THE BOARD OF REGENTS OF THE UNIVERITY OF TEXAS SYSTEM
    Inventors: Igor C. Almeida, Katja Michael, Nathaniel Schocker
  • Patent number: 10279023
    Abstract: Use of synthetic peptides derived from Trypanosoma cruzi antigens and their use in vaccination against trypomastigote infection and Chagas disease. T. cruzi uses several surface proteins to invade the host. In their role of protection, the surface protients ensure the targeting and invasion of specific cells or tissues. A conserved region in the family of mucin-associated surface proteins (MASP) was used to analyze the expression of MASP at different points of invasion and proved to be important for host cell invasion, thus suggesting MASP as a candidate for vaccine development. A synthetic peptide, MASPsyn, was studied and showed efficacy in stimulating antibody and cytokine production necessary for resistance against the parasite.
    Type: Grant
    Filed: February 13, 2017
    Date of Patent: May 7, 2019
    Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Rosa A. Maldonado, Carylinda Serna, Igor C. Almeida
  • Publication number: 20170333568
    Abstract: Certain embodiments are directed to method for synthesizing and using glycoconjugates on the immunodominant epitope Gal?(1,3)Gal?(3(1,4)GlcNAc? (Gal?3LN?).
    Type: Application
    Filed: October 31, 2015
    Publication date: November 23, 2017
    Applicant: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Igor C. ALMEIDA, Katja MICHAEL, Nathaniel SCHOCKER
  • Patent number: 9566320
    Abstract: Use of synthetic peptides derived from Trypanosoma cruzi antigens and their use in vaccination against trypomastigote infection and Chagas disease. T. cruzi uses several surface proteins to invade the host. In their role of protection, the surface protients ensure the targeting and invasion of specific cells or tissues. A conserved region in the family of mucin-associated surface proteins (MASP) was used to analyze the expression of MASP at different points of invasion and proved to be important for host cell invasion, thus suggesting MASP as a candidate for vaccine development. A synthetic peptide, MASPsyn, was studied and showed efficacy in stimulating antibody and cytokine production necessary for resistance against the parasite.
    Type: Grant
    Filed: September 24, 2014
    Date of Patent: February 14, 2017
    Assignee: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Rosa A. Maldonado, Carylinda Serna, Igor C. Almeida
  • Publication number: 20150086583
    Abstract: Use of synthetic peptides derived from Trypanosoma cruzi antigens and their use in vaccination against trypomastigote infection and Chagas disease. T. cruzi uses several surface proteins to invade the host. In their role of protection, the surface protients ensure the targeting and invasion of specific cells or tissues. A conserved region in the family of mucin-associated surface proteins (MASP) was used to analyze the expression of MASP at different points of invasion and proved to be important for host cell invasion, thus suggesting MASP as a candidate for vaccine development. A synthetic peptide, MASPsyn, was studied and showed efficacy in stimulating antibody and cytokine production necessary for resistance against the parasite.
    Type: Application
    Filed: September 24, 2014
    Publication date: March 26, 2015
    Inventors: Rosa A. Maldonado, Carylinda Serna, Igor C. Almeida
  • Patent number: 6682900
    Abstract: A chemiluminescent (CL)-ELISA method with purified and complex antigens of Trypanosoma cruzi is proposed for the specific and sensitive diagnosis of Chagas' disease in patients and blood bank samples. A trypomastigote specific antigen (A&T) together with an epimastigote extract (EpEx), used as a control of sensitivity, are the preparations used. The high sensitivity of the CL-ELISA method permits the use of extremely small amounts of antigen and allows a serum dilution in routine tests as high as 1:2000, thus reducing the nonspecific or false-positive reactions to a minimum. The use of the A&T purified antigen eliminates cross-reactivities with other infectious agents, detects active infection, and serves to monitor chemotherapy in chronic patients. The use of the EpEx antigenic preparation not only confirms the positive results with A&T but also, in case of discrepancy, suggests other infections such as leishmaniasis.
    Type: Grant
    Filed: September 21, 2000
    Date of Patent: January 27, 2004
    Assignee: Fundação Hemocentro de Ribeirão Preto
    Inventors: Luiz R. R. G. Travassos, Igor C. Almeida, Dimas Tadeu Covas